Intuitive Surgical Inc (ISRG) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Intuitive Surgical Inc (ISRG) has a cash flow conversion efficiency ratio of 0.058x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($1.06 Billion) by net assets ($18.30 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see ISRG market cap for the company's overall valuation and market capitalisation.
Intuitive Surgical Inc - Cash Flow Conversion Efficiency Trend (1999–2025)
This chart illustrates how Intuitive Surgical Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Intuitive Surgical Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Intuitive Surgical Inc ranked by their cash flow conversion efficiency. Explore Intuitive Surgical Inc cash earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Delta Electronics Inc
TW:2308
|
0.123x |
|
Airbus Group SE
PA:AIR
|
-0.063x |
|
The TJX Companies Inc
NYSE:TJX
|
0.108x |
|
Sony Group Corp
NYSE:SONY
|
0.022x |
|
Deutsche Telekom AG
F:DTEA
|
0.097x |
|
Siemens Energy AG
F:ENR
|
0.272x |
|
IBERDROLA ADR/1 EO 3
F:IBE5
|
N/A |
|
Eaton Corporation PLC
F:3EC
|
0.026x |
Annual Cash Flow Conversion Efficiency for Intuitive Surgical Inc (1999–2025)
The table below shows the annual cash flow conversion efficiency of Intuitive Surgical Inc from 1999 to 2025. View Intuitive Surgical Inc (ISRG) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $17.94 Billion | $3.03 Billion | 0.169x | +15.61% |
| 2024-12-31 | $16.53 Billion | $2.42 Billion | 0.146x | +7.92% |
| 2023-12-31 | $13.40 Billion | $1.81 Billion | 0.135x | +0.92% |
| 2022-12-31 | $11.11 Billion | $1.49 Billion | 0.134x | -23.26% |
| 2021-12-31 | $11.95 Billion | $2.09 Billion | 0.175x | +14.91% |
| 2020-12-31 | $9.76 Billion | $1.48 Billion | 0.152x | -21.13% |
| 2019-12-31 | $8.28 Billion | $1.60 Billion | 0.193x | +10.30% |
| 2018-12-31 | $6.69 Billion | $1.17 Billion | 0.175x | -27.73% |
| 2017-12-31 | $4.73 Billion | $1.14 Billion | 0.242x | +34.07% |
| 2016-12-31 | $5.78 Billion | $1.04 Billion | 0.181x | +1.01% |
| 2015-12-31 | $4.32 Billion | $771.90 Million | 0.179x | -9.20% |
| 2014-12-31 | $3.38 Billion | $665.10 Million | 0.197x | -21.69% |
| 2013-12-31 | $3.50 Billion | $880.00 Million | 0.251x | +10.51% |
| 2012-12-31 | $3.58 Billion | $814.20 Million | 0.227x | -11.21% |
| 2011-12-31 | $2.65 Billion | $677.60 Million | 0.256x | -1.17% |
| 2010-12-31 | $2.04 Billion | $528.00 Million | 0.259x | +3.46% |
| 2009-12-31 | $1.54 Billion | $385.06 Million | 0.250x | +14.04% |
| 2008-12-31 | $1.27 Billion | $278.24 Million | 0.220x | -5.10% |
| 2007-12-31 | $888.67 Million | $205.69 Million | 0.231x | +36.70% |
| 2006-12-31 | $589.71 Million | $99.84 Million | 0.169x | +5.86% |
| 2005-12-31 | $442.59 Million | $70.79 Million | 0.160x | +66.15% |
| 2004-12-31 | $314.93 Million | $30.32 Million | 0.096x | +441.89% |
| 2003-12-31 | $278.96 Million | $-7.85 Million | -0.028x | +87.33% |
| 2002-12-31 | $63.68 Million | $-14.15 Million | -0.222x | +6.24% |
| 2001-12-31 | $78.29 Million | $-18.55 Million | -0.237x | -67.92% |
| 2000-12-31 | $90.73 Million | $-12.80 Million | -0.141x | +80.32% |
| 1999-12-31 | $22.21 Million | $-15.93 Million | -0.717x | -- |
About Intuitive Surgical Inc
Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. It offers the da Vinci Surgical System that enables surgical procedures using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings… Read more